Submitted:
21 May 2024
Posted:
22 May 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
Research Ethics
References
- Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021, 384, 403–416. [Google Scholar] [CrossRef] [PubMed]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Perez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020, 383, 2603–2615. [Google Scholar] [CrossRef]
- Feinmann, J. Covid-19: Global vaccine production is a mess and shortages are down to more than just hoarding. BMJ 2021, 375, n2375. [Google Scholar] [CrossRef] [PubMed]
- Muric, G.; Wu, Y.; Ferrara, E. COVID-19 Vaccine Hesitancy on Social Media: Building a Public Twitter Data Set of Antivaccine Content, Vaccine Misinformation, and Conspiracies. JMIR Public Health Surveill 2021, 7, e30642. [Google Scholar] [CrossRef]
- Wouters, O.J.; Shadlen, K.C.; Salcher-Konrad, M.; Pollard, A.J.; Larson, H.J.; Teerawattananon, Y.; Jit, M. Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment. Lancet 2021, 397, 1023–1034. [Google Scholar] [CrossRef]
- Majid, U.; Ahmad, M.; Zain, S.; Akande, A.; Ikhlaq, F. COVID-19 vaccine hesitancy and acceptance: A comprehensive scoping review of global literature. Health Promot Int 2022, 37. [Google Scholar] [CrossRef] [PubMed]
- Peters, M.D.J. Addressing vaccine hesitancy and resistance for COVID-19 vaccines. Int J Nurs Stud 2022, 131, 104241. [Google Scholar] [CrossRef]
- Solis Arce, J.S.; Warren, S.S.; Meriggi, N.F.; Scacco, A.; McMurry, N.; Voors, M.; Syunyaev, G.; Malik, A.A.; Aboutajdine, S.; Adeojo, O.; et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med 2021, 27, 1385–1394. [Google Scholar] [CrossRef] [PubMed]
- Ackah, B.B.B.; Woo, M.; Stallwood, L.; Fazal, Z.A.; Okpani, A.; Ukah, U.V.; Adu, P.A. COVID-19 vaccine hesitancy in Africa: A scoping review. Glob Health Res Policy 2022, 7, 21. [Google Scholar] [CrossRef]
- Parimi, K.; Gilkeson, K.; Creamer, B.A. COVID-19 vaccine hesitancy: Considerations for reluctance and improving vaccine uptake. Hum Vaccin Immunother 2022, 18, 2062972. [Google Scholar] [CrossRef]
- Wu, J.; Li, Q.; Silver Tarimo, C.; Wang, M.; Gu, J.; Wei, W.; Ma, M.; Zhao, L.; Mu, Z.; Miao, Y. COVID-19 Vaccine Hesitancy Among Chinese Population: A Large-Scale National Study. Front Immunol 2021, 12, 781161. [Google Scholar] [CrossRef]
- Reiter, P.L.; Pennell, M.L.; Katz, M.L. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? Vaccine 2020, 38, 6500–6507. [Google Scholar] [CrossRef]
- Wang, J.; Jing, R.; Lai, X.; Zhang, H.; Lyu, Y.; Knoll, M.D.; Fang, H. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. Vaccines (Basel) 2020, 8, 482. [Google Scholar] [CrossRef] [PubMed]
- Kelly, B.J.; Southwell, B.G.; McCormack, L.A.; Bann, C.M.; MacDonald, P.D.M.; Frasier, A.M.; Bevc, C.A.; Brewer, N.T.; Squiers, L.B. Predictors of willingness to get a COVID-19 vaccine in the U.S. BMC Infect Dis 2021, 21, 338. [Google Scholar] [CrossRef]
- Bou Hamdan, M.; Singh, S.; Polavarapu, M.; Jordan, T.R.; Melhem, N.M. COVID-19 vaccine hesitancy among university students in Lebanon. Epidemiol Infect 2021, 149, e242. [Google Scholar] [CrossRef] [PubMed]
- Kasrine Al Halabi, C.; Obeid, S.; Sacre, H.; Akel, M.; Hallit, R.; Salameh, P.; Hallit, S. Attitudes of Lebanese adults regarding COVID-19 vaccination. BMC Public Health 2021, 21, 998. [Google Scholar] [CrossRef]
- Kricorian, K.; Civen, R.; Equils, O. COVID-19 vaccine hesitancy: Misinformation and perceptions of vaccine safety. Hum Vaccin Immunother 2022, 18, 1950504. [Google Scholar] [CrossRef]
- Sax, J.K. COVID-19 Vaccine Hesitancy and (Mis)perception of Risk. Am J Law Med 2022, 48, 54–90. [Google Scholar] [CrossRef]
- Pogue, K.; Jensen, J.L.; Stancil, C.K.; Ferguson, D.G.; Hughes, S.J.; Mello, E.J.; Burgess, R.; Berges, B.K.; Quaye, A.; Poole, B.D. Influences on Attitudes Regarding Potential COVID-19 Vaccination in the United States. Vaccines (Basel) 2020, 8, 582. [Google Scholar] [CrossRef] [PubMed]
- Kessel, M. Restoring the pharmaceutical industry's reputation. Nat Biotechnol 2014, 32, 983–990. [Google Scholar] [CrossRef]
- Singh, Y.; Eisenberg, M.D.; Sood, N. Factors Associated With Public Trust in Pharmaceutical Manufacturers. JAMA Netw Open 2023, 6, e233002. [Google Scholar] [CrossRef] [PubMed]
- Rodrigues, F.; Ziade, N.; Jatuworapruk, K.; Caballero-Uribe, C.V.; Khursheed, T.; Gupta, L. The Impact of Social Media on Vaccination: A Narrative Review. J Korean Med Sci 2023, 38, e326. [Google Scholar] [CrossRef] [PubMed]
- MacDonald, N.E.; Hesitancy, S.W.G.o.V. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015, 33, 4161–4164. [Google Scholar] [CrossRef] [PubMed]
- Hanna, P.; Issa, A.; Noujeim, Z.; Hleyhel, M.; Saleh, N. Assessment of COVID-19 vaccines acceptance in the Lebanese population: A national cross-sectional study. J Pharm Policy Pract 2022, 15, 5. [Google Scholar] [CrossRef] [PubMed]
- Nasr, L.; Saleh, N.; Hleyhel, M.; El-Outa, A.; Noujeim, Z. Acceptance of COVID-19 vaccination and its determinants among Lebanese dentists: A cross-sectional study. BMC Oral Health 2021, 21, 484. [Google Scholar] [CrossRef]
- Kreps, S.; Prasad, S.; Brownstein, J.S.; Hswen, Y.; Garibaldi, B.T.; Zhang, B.; Kriner, D.L. Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination. JAMA Netw Open 2020, 3, e2025594. [Google Scholar] [CrossRef] [PubMed]
- Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 2021, 27, 225–228. [Google Scholar] [CrossRef] [PubMed]
- Nazli, S.B.; Yigman, F.; Sevindik, M.; Deniz Ozturan, D. Psychological factors affecting COVID-19 vaccine hesitancy. Ir J Med Sci 2022, 191, 71–80. [Google Scholar] [CrossRef] [PubMed]
- Tram, K.H.; Saeed, S.; Bradley, C.; Fox, B.; Eshun-Wilson, I.; Mody, A.; Geng, E. Deliberation, Dissent, and Distrust: Understanding Distinct Drivers of Coronavirus Disease 2019 Vaccine Hesitancy in the United States. Clin Infect Dis 2022, 74, 1429–1441. [Google Scholar] [CrossRef]
- Caiazzo, V.; Witkoski Stimpfel, A. Vaccine hesitancy in American healthcare workers during the COVID-19 vaccine roll out: An integrative review. Public Health 2022, 207, 94–104. [Google Scholar] [CrossRef]
- Youssef, D.; Abou-Abbas, L.; Berry, A.; Youssef, J.; Hassan, H. Determinants of acceptance of Coronavirus disease-2019 (COVID-19) vaccine among Lebanese health care workers using health belief model. PLoS ONE 2022, 17, e0264128. [Google Scholar] [CrossRef] [PubMed]
- Freeman, D.; Loe, B.S.; Chadwick, A.; Vaccari, C.; Waite, F.; Rosebrock, L.; Jenner, L.; Petit, A.; Lewandowsky, S.; Vanderslott, S.; et al. COVID-19 vaccine hesitancy in the UK: The Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychol Med 2022, 52, 3127–3141. [Google Scholar] [CrossRef] [PubMed]
- Prati, G. Intention to receive a vaccine against SARS-CoV-2 in Italy and its association with trust, worry and beliefs about the origin of the virus. Health Educ Res 2020, 35, 505–511. [Google Scholar] [CrossRef]
| Variable | US cohort (N = 6,775) |
Lebanese cohort (N = 422) |
Total (N = 7,197) |
p-value |
|---|---|---|---|---|
| Age, years | < 0.001 | |||
| 18-39 | 2,358/6,644 (35.5) | 308/422 (73.0) | 266/7,066 (37.7) | |
| 40-59 | 2,080/6,644 (31.3) | 93/422 (22.0) | 2,173/7,066 (30.8) | |
| ≥ 60 | 2,206/6,644 (33.2) | 21/422 (5.0) | 2227/7,066 (31.5) | |
| Gender | < 0.001 | |||
| Male | 1,442/6,443 (21.7) | 128/422 (30.3) | 1,570/7,065 (22.2) | |
| Female | 5,055/6,443 (76.1) | 291/422 (69.0) | 5,346/7,065 (75.7) | |
| Other | 146/6,443 (2.2) | 3/422 (0.7) | 149/7,065 (2.1) | |
| Health care worker | 1,807/6,443 (26.7) | 124/422 (29.4) | 1,931/7,065 (26.8) | 0.22 |
| Education | < 0.001 | |||
| Less than high school | 21/6,654 (0.3) | 0/422 (0.0) | 21/7,076 (0.3) | |
| Completed high school | 1,113/6,654 (16.7) | 28/422 (6.6) | 1,141/7,076 (16.1) | |
| Undergraduate degree | 2,660/6,654 (40) | 129/422 (30.6) | 2,789/7,076 (39.4) | |
| Graduate degree | 2,226/6,654 (33.5) | 265/422 (62.8) | 2,491/7,076 (35.2) | |
| Doctoral | 634/6,654 (9.5) | 0/422 (0.0) | 634/7,076 (9.0) | |
| Alcohol consumption | < 0.001 | |||
| Never | 2,665/6,638 (40.1) | 24/422 (57.6) | 2,908/7,060 (41.2) | |
| 1-2 drinks/week | 2,322/6,638 (35.0) | 156/422 (37.0) | 2,478/7,080 (35.1) | |
| 3-5 drinks/week | 947/6,638 (14.3) | 17/422 (4.0) | 964/7,060 (13.7) | |
| > 5 drinks/week | 704/6,638 (10.6) | 6/422 (1.4) | 710/7,060 (10.1) | |
| Smoking | < 0.001 | |||
| Never smoked | 5,215/6,648 (93.5) | 330/422 (78.2) | 6,545/7,070 (92.6) | |
| < 1/2 pack daily | 252/6,648 (3.8) | 54/422 (12.8) | 306/7,070 (4.3) | |
| > 1/2 pack daily | 181/6,648 (2.7) | 38/422 (9) | 219/7,070 (3.1) | |
| Exercise | < 0.001 | |||
| Never | 2,543/6,665 (38.2) | 112/422 (26.5) | 2,655/7,087 (37.5) | |
| ≤ 3 days/week | 2,689/6,665(40.3) | 225/422 (53.3) | 2,914/7,087 (41.1) | |
| > 3 days/week | 1433/6,665 (21.5) | 85/422 (20.1) | 1,518/7,087 (21.4) | |
| Health status | < 0.001 | |||
| Healthy | 2,554/6,775 (37.7) | 323/422 (76.5) | 2,877/7,197 (40.0) | |
| Preexisting condition | 4,221/6,775 (62.3) | 99/422 (23.5) | 4,320/7,197 (60.0) | |
| Health perception | 0.61 | |||
| Poor | 444/6,627 (6.7) | 24/422 (5.7) | 468/7,049 (6.6) | |
| Good | 3,262/6,627 (49.2) | 221/422 (52.4) | 3,483/7,049 (49.4) | |
| Very good | 2,247/6,627 (33.9) | 137/422 (32.5) | 2,384/7,049 (33.8) | |
| Excellent | 674/6,627 (10.2) | 40/422 (9.5) | 714/7,049 (10.1) | |
| Previous personal diagnosis of COVID-19 | 539/6,654 (8.1) | 95/422 (22.5) | 634/7,076 (9.0) | < 0.001 |
| History of COVID-19 in family or friends | 4,259/6,653 (64.0) | 339/422 (80.3) | 4,528/7,075 (65.0) | < 0.001 |
| How often do you take the influenza vaccine? | < 0.001 | |||
| Never | 882/6,649 (13.3) | 209/422 (49.5) | 1,091/7,071 (15.4) | |
| Yearly | 5070/6,649 (76.3) | 108/422 (25.6) | 5,178/7,071 (73.2) | |
| Once | 697/6,649 (10.5) | 105/422 (24.9) | 802/7,071 (11.3) | |
| I am willing to take the COVID-19 vaccine | < 0.001 | |||
| Definitely yes | 5,846/6,655 (87.8) | 368/422 (87.2) | 6,214/7,077 (87.8) | |
| Definitely no | 305/6,655 (4.6) | 5/422 (1.2) | 310/7,077 (4.4) | |
| Undecided/likely | 286/6,655 (4.3) | 33/422 (7.8) | 319/7,077 (4.5) | |
| Undecided/unlikely | 218/6,655 (3.3) | 16/422 (3.8) | 23/7,077 (3.3) |
| Knowledge question | US cohort (N = 6,775) |
Lebanese cohort (N = 422) |
Total (N = 7,197) |
p-value |
|---|---|---|---|---|
| Questions where the expected answer is “True” | ||||
| COVID-19 symptoms may include cough, diarrhea, and fever | 6,197/6,775 (91.5) |
4/18/422 (99.1) |
6,6615/7,197 (91.9) |
< 0.001 |
| COVID-19 can present without fever | 6,231/6,775 (92.0) |
396/422 (93.6) |
6,626/7,197 (92.1) |
0.23 |
| COVID-19 spreads through respiratory droplets produced when an infected person coughs, sneezes or talks | 6,585/6,775 (97.2) |
416/422 (98.6) |
7,001/7,197 (97.3) |
0.09 |
| Questions where the expected answer is “False” | ||||
| Flu vaccine provides some protection against COVID-19 as well | 6,269/6,775 (92.5) |
401/422 (95.0) |
6,670/7,197 (92.7) |
0.06 |
| Patients who recover from COVID-19 infection develop lifelong immunity | 6,652/6,775 (98.2) |
410/422 (97.2) |
7,062/7,197 (98.1) |
0.14 |
| If I have allergies, I should not take the COVID-19 vaccine | 6,397/6,775 (94.4) |
380/422 (90.0) |
6,777/7,197 (94.2) |
< 0.001 |
| During the trials, serious adverse events and deaths occurred as a result of the vaccine | 5,487/6,775 (81.0) |
353/422 (83.6) |
5,840/7,197 (81.1) |
0.17 |
| The COVID-19 vaccine can change human DNA | 816/6,775 (12.0) |
161/422 (38.2) |
977/7,197 (13.6) |
< 0.001 |
| The COVID-19 vaccine can sometimes lead to infertility | 382/6,775 (5.6) |
149/422 (35.5) |
531/7,197 (7.4) |
< 0.001 |
| The COVID-19 vaccine can be used to acquire my health data or track me | 344/6,775 (5.1) |
172/422 (40.8) |
516/7,197 (7.2) |
< 0.001 |
| Attitude and perception | US cohort (N = 6,775) |
Lebanese cohort (N = 422) |
Total (N = 7,197) |
p-value |
|---|---|---|---|---|
| The benefits from most routine vaccinations outweigh the risks or side effects | 6,372/6,622 (96.2) |
365/422 (86.5) |
6,737/7,044 (95.8) |
< 0.001 |
| Vaccination is an effective strategy to control the pandemic | 6,241/6,610 (94.4) |
414/422 (98.1) |
6,655/7,032 (94.6) |
0.001 |
| The virus causing COVID-19 was created in a laboratory | 1,168/6,515 (17.9) |
153/422 (36.3) |
1,321/6,937 (19.0) |
< 0.001 |
| The COVID-19 vaccine development was rushed | 2,506/6,635 (37.8) |
217/422 (51.4) |
2,723/7,057 (38.6) |
< 0.001 |
| The COVID-19 vaccine is more dangerous than the COVID-19 infection | 208/6,598 (3.2) |
22/422 (5.2) |
230/7,020 (3.3) |
0.21 |
| COVID-19 infection does not worry me | 1,889/6,624 (28.5) |
75/417 (18.0) |
1,964/7,041 (27.9) |
< 0.001 |
| My likelihood of becoming infected with COVID-19 is | < 0.001 | |||
| Very likely | 442/6,605 (6.7) |
103/422 (24.4) |
545/7,072 (7.8) |
|
| Likely | 2,112/6,605 (32.0) |
217/422 (51.4) |
2,329/7,027 (33.1) |
|
| Not likely | 4,051/6,605 (61.3) |
102/422 (24.4) |
4,153/7,027 (59.1) |
|
| How would you rate your knowledge of COVID-19? | < 0.001 | |||
| Excellent | 777/6,617 (11.7) |
7/422 (1.7) |
784/7,039 (11.1) |
|
| Very good | 2,637/6,617 (39.9) |
158/422 (37.4) |
2,795/7,039 (39.7) |
|
| Good | 3,975/6,617 (45.0) |
170/422 (40.3) |
3,145/7,039 (44.7) |
|
| Poor | 228/6,617 (3.4) |
87/422 (20.6) |
315/7,039 (14.5) |
|
| I would get the COVID-19 vaccine if my healthcare provider recommends it | 5,969/6,588 (90.6) |
349/419 (83.3) |
6,318/7,007 (90.2) |
< 0.001 |
| My healthcare provider advised me not to take the COVID-19 vaccine | 87/6,216 (1.4) |
12/422 (2.8) |
99/6,638 (1.5) |
0.18 |
| Main sources of health information | ||||
| Healthcare provider | 5,272/6,775 (77.8) |
275/422 (65.2) |
5,547/7,197 (77.1) |
< 0.001 |
| Family | 4,562/6,775 (67.3) |
123/422 (29.1) |
4,685/7,197 (65.1) |
< 0.001 |
| General media | 4,426/6,775 (65.1) |
137/422 (32.5) |
4,563/7,197 (63.4) |
< 0.001 |
| Social media | 4,186/6,775 (61.8) |
147/422 (34.8) |
4,333/7,197 (60.2) |
< 0.001 |
| Variable | US cohort (N = 6,775) | Lebanese cohort (N = 422) | ||
|---|---|---|---|---|
| aOR (95% CI) | p-value | aOR (95% CI) | p-value | |
| The COVID-19 vaccine is more dangerous than the COVID-19 infection | 8.7 (3.1-24.3) | < 0.001 | 9.4 (3.3-26.7) | < 0.001 |
| My healthcare provider advised me not to take the COVID-19 vaccine | 6.5 (2.9-14.2) | < 0.001 | 5.4 (1.0-28.4) | 0.04 |
| The benefits from most routine vaccinations outweigh the risks or side effects | 5.4 (2.7-10.8) | < 0.001 | ||
| The COVID-19 vaccine development was rushed | 3.2 (2.4-4.2) | < 0.001 | 3.7 (1.7-8.2) | < 0.001 |
| The virus causing COVID-19 was created in a laboratory | 2.9 (2.2-4.0) | < 0.001 | ||
| Healthcare worker | 2.2 (1.6-3.2) | < 0.001 | 3.3 (1.2-9.0) | 0.02 |
| COVID-19 infection does not worry me | 2.0 (1.5-2.7) | < 0.001 | ||
| Previous personal COVID diagnosis | 1.6 (1.1-2.5) | 0.02 | ||
| Smoking | 1.6 (1.2-2.2) | 0.001 | ||
| How would you rate your knowledge of COVID-19 | 1.4 (1.1-1.7) | 0.001 | ||
| Knowledge score | 1.3 (1.1-1.5) | 0.002 | 0.7 (0.6-0.9) | 0.02 |
| Education | 0.8 (0.7-0.9) | 0.004 | 0.6 (0.3-0.9) | 0.02 |
| How often do you take the influenza vaccine? | 0.6 (0.5-0.8) | < 0.001 | ||
| Age | 0.6 (0.5-0.7) | < 0.001 | 0.4 (0.2-0.8) | 0.01 |
| Vaccination is an effective strategy to control the pandemic | 0.3 (0.2-0.5) | < 0.001 | ||
| I would get the COVID-19 vaccine if my healthcare provider recommends it | 0.02 (0.01-0.03) | < 0.001 | 0.4 (0.2-0.9) | 0.03 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).